TRIBE
Regimen
- Experimental
- FOLFOXIRI + bevacizumab
- Control
- FOLFIRI + bevacizumab
Population
Metastatic CRC, 1L, previously untreated; fit patients (good PS), all RAS/BRAF status.
Key finding
1L mCRC (unresectable, age ≤75, ECOG 0-2): mPFS 12.1 vs 9.7 mo (HR 0.75, 95% CI 0.62-0.90, p=0.003); ORR 65% vs 53% (p=0.006); mOS 29.8 vs 25.8 mo (HR 0.80, 95% CI 0.65-0.98, p=0.03) in updated analysis (Lancet Oncol 2015); grade 3-4 diarrhea 18.8% vs 10.6%, neurotoxicity 5.0% vs 0.4%
Source: PMID 25337750
Timeline
Guideline citations
- NCCN Colon (p.59)
- NCCN Rectal (p.76)